TAK-573-2001: Modakafusp alfa in Combination with Daratumumab for the Treatment of Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Sponsor: Takeda Development Center Americas, Inc
TAK-573-2001: A Phase 1/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Modakafusp Alfa in Combination With Daratumumab Subcutaneous in Patients With Relapsed or Refractory Multiple Myeloma
Modakafusp alfa in combination with daratumumab for the treatment of relapsed/refractory multiple myeloma.
Treatment history must be one of:
- Three prior lines of treatment including at least 1 proteasome inhibitor (PI), 1 immunomodulatory drug (IMiD), and 1 anti-CD38 antibody.
- Triple refractory to a PI, IMiD, and anti-CD38 antibody regardless of the number of lines of therapy.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.